8-K: Neurocrine Biosciences Reports Strong 2023 Results and Provides Optimistic 2024 Guidance

Neurocrine Biosciences announced robust financial results for 2023, driven by strong sales of INGREZZA, and provided positive financial guidance for 2024.

Summary

• Neurocrine Biosciences reported its fourth quarter and full year 2023 financial results, showcasing significant growth.
• INGREZZA net product sales reached $500 million in the fourth quarter and $1.84 billion for the full year, representing year-over-year growth of 25% and 29%, respectively.
• The company anticipates INGREZZA net product sales to be between $2.1 and $2.2 billion in 2024.
• Neurocrine plans to submit a regulatory application for crinecerfont in the second quarter of 2024 for the treatment of congenital adrenal hyperplasia.
• Total revenues for the fourth quarter of 2023 were $515.2 million, compared to $412.0 million in the same period of 2022.
• Full year 2023 total revenues reached $1.887 billion, up from $1.488 billion in 2022.
• GAAP net income for the fourth quarter was $147.7 million, or $1.44 per diluted share, compared to $89.0 million, or $0.88 per diluted share, in the fourth quarter of 2022.
• Full year GAAP net income was $249.7 million, or $2.47 per diluted share, compared to $154.5 million, or $1.56 per diluted share, in 2022.
• The company's cash, cash equivalents, and marketable securities totaled approximately $1.7 billion as of December 31, 2023.
• The company has resolved all patent litigation regarding generic versions of INGREZZA, with generic entry not expected until March 2038 at the earliest.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to strong financial results, positive future guidance, and significant pipeline progress. The resolution of patent litigation and the Breakthrough Therapy designation for crinecerfont further contribute to the positive outlook.

Positives

• INGREZZA sales are showing strong growth, indicating a successful commercial strategy.
• The company has a robust cash position, providing financial flexibility for future investments.
• The resolution of patent litigation provides long-term market exclusivity for INGREZZA.
• The Breakthrough Therapy designation for crinecerfont highlights its potential to address an unmet medical need.
• The company has a diverse pipeline with multiple compounds in midto late-phase clinical development.
• The company is making significant progress towards becoming a leading neuroscience focused company.

Negatives

• Research and development expenses have increased, reflecting the company's investment in its pipeline.
• Selling, general, and administrative expenses have also increased, primarily due to commercial initiatives supporting INGREZZA growth.
• The company's collaboration revenue decreased from $47.8 million in 2022 to $26.5 million in 2023.

Risks

• The company's future financial performance is dependent on the continued success of INGREZZA.
• There are risks associated with the development of the company's product candidates, including potential regulatory hurdles.
• The company relies on third parties for development, manufacturing, and commercialization activities.
• There is competition from other therapies and potential generic entrants for the company's products.
• Government and third-party regulatory and/or policy efforts may impose sales and pharmaceutical pricing controls.

Future Outlook

The company expects INGREZZA net product sales to be between $2.1 and $2.2 billion in 2024. They also provided guidance for GAAP and non-GAAP R&D and SG&A expenses for 2024. The company anticipates several pipeline milestones in 2024, including the submission of a New Drug Application for crinecerfont and top-line data from multiple Phase 2 studies.

Management Comments

• Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences, stated he is exceptionally proud of the progress made with INGREZZA in 2023.
• He also noted the positive Phase 3 crinecerfont results open the door to help patients with congenital adrenal hyperplasia.
• He believes the company is making significant progress towards becoming a leading neuroscience focused company.

Industry Context

This announcement reflects the ongoing growth in the neuroscience pharmaceutical sector, with a focus on treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company's success with INGREZZA and the potential of crinecerfont position it as a key player in this space. The resolution of patent litigation is also a significant development in the competitive landscape.

Comparison to Industry Standards

• Neurocrine's 29% year-over-year growth in INGREZZA sales is strong compared to the average growth rate of established pharmaceutical products.
• The company's focus on neuroscience is aligned with the industry trend of developing targeted therapies for complex neurological conditions.
• The projected $2.1 $2.2 billion in INGREZZA sales for 2024 places it in the upper tier of revenue-generating products for companies of its size.
• The company's pipeline is diverse, with multiple compounds in midto late-stage development, which is a positive sign compared to companies with a more limited pipeline.
• Competitors such as Teva Pharmaceuticals and AbbVie also have products in the neuroscience space, but Neurocrine's focus on specific conditions like tardive dyskinesia and congenital adrenal hyperplasia gives it a unique position.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and positive future guidance.
• Employees may be motivated by the company's success and pipeline progress.
• Patients may benefit from the company's development of new treatments for neurological, neuroendocrine, and neuropsychiatric disorders.
• Suppliers and creditors may view the company as a stable and reliable partner.

Next Steps

• The company plans to submit a New Drug Application for crinecerfont in the second quarter of 2024.
• The company expects top-line Phase 2 data for Efmody, NBI-1065845, and other pipeline programs in 2024.
• The company will initiate Phase 2 studies for NBI-1070770 and Phase 1 studies for NBI-1117567, NBI-1076986, and NBI-1065890.

Key Dates

Keywords

Neurocrine Biosciences, INGREZZA, valbenazine, crinecerfont, tardive dyskinesia, congenital adrenal hyperplasia, financial results, pharmaceutical, biotechnology, neuroscience